Surgical critical care: Fungal infections in surgical patients

Critical Care Medicine

Volumn 34, Issue SUPPL. 9, 2006, Pages

  Lipsett, Pamela A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Candida; Diagnosis; Epidemiology; Fungus; Prevention; Risk factors; Therapy

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIBIOTIC AGENT; BETA 1,3 GLUCAN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; MICAFUNGIN; MICONAZOLE; NYSTATIN; PLACEBO; POSACONAZOLE; RAVUCONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDIASIS; CLINICAL TRIAL; COST OF ILLNESS; CRITICALLY ILL PATIENT; FUNGUS CULTURE; HUMAN; IMMUNE DEFICIENCY; INFECTION PREVENTION; INTENSIVE CARE; INTENSIVE CARE UNIT; MYCOSIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; SURGICAL PATIENT;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CRITICAL CARE; CROSS INFECTION; HUMANS; INTENSIVE CARE UNITS; POSTOPERATIVE COMPLICATIONS; RISK ASSESSMENT; RISK FACTORS;

EID: 33747422092     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000231883.93001.E0     Document Type: Review

References (88)

1. Blumberg HM, Jarvis WR, Soucie JM, et al: Risk factors for candidal bloodstream infections in surgical intensive care unit patients: The NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001; 33:177-186
2. Trick WE, Fridkin SK, Edwards JR, et al: Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35:627-630
3. Beck-Sagué CM, Jarvis WM: Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990: The National Nosocomial Infections Surveillance System. J Infect Dis 1993; 167:1247-1251
4. Centers for Disease Control: National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003; 31:481-498
5. Wey SB, Mori M, Pfaller MA, et al: Risk factors for hospital-acquired candidemia: A matched case-control study. Arch Intern Med 1989; 149:2349-2353
6. Wey SB, Mori M, Pfaller MA, et al: Hospital-acquired candidemia: The attributable mortality and excess length of stay. Arch Intern Med 1988; 148:2642-2645
7. Fraser VJ, Jones M, Dunkel J, et al: Candidemia in a tertiary care hospital: Epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15:414-421
8. Pittet D, Monod M, Suter PM, et al: Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994; 220:751-758
9. Sandford GR, Merz WG, Wingard JR, et al: The value of fungal surveillance cultures as predictors of systemic fungal infections. J Infect Dis 1980; 142:503-509
10. Samonis G, Gikas A, Anaissie EJ, et al: Prospective evaluation of effects of broad spectrum antibiotics on gastrointestinal yeast colonization of humans. Antimicrob Agents Chemother 1993; 37:51-53
11. Kennedy MJ, Volz PA: Effect of various antibiotics on gastrointestinal colonization and dissemination by Candida albicans. Sabouraudia 1985; 23:265-273
12. Slotman GJ, Shapiro E, Moffa SM: Fungal sepsis: Multisite colonization versus fungemia. Am Surg 1994; 60:107-113
13. Lipsett PA: Clinical trials of antifungal prophylaxis among patients in surgical intensive care units: Concepts and considerations. Clin Infect Dis 2004; 39:S193-S199
14. Jarvis WR: Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995; 20:1526-1530
15. Kao AS, Brandt ME, Pruitt WR, et al: The epidemiology of candidemia in two United States cities: Results of a population-based active surveillance. Clin Infect Dis 1999; 29: 1164-1170
16. Abi-Said D, Anaissie E, Uzun O, et al: The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24:1122-1128
17. Nguyen MH, Peacock JE Jr, Morris AJ, et al: The changing face of candidemia: Emergence of non-C. albicans species and antifungal resistance. Am J Med 1996; 100:617-623
18. Pfaller MA, Jones RN, Messer SA, et al: National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn Microbiol Infect Dis 1998; 30:121-129
19. National Committee for Clinical Laboratory Standards (NCCLS): Reference method for broth dilution antifungal susceptibility testing of yeasts: Approved standard. NCCLS document M27-A. Wayne, PA, NCCLS, 1997
20. Marr KA, White TC, van Burik JAH, et al: Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin Infect Dis 1997; 25: 908-910
21. Wingard JR, Merz WG, Rinaldi MG, et al: Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 199; 325: 1274-1277
22. Wingard JR, Merz WG, Rinaldi MG, et al: Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993; 37:1847-1849
23. Rex JH, Pfaller MA, Galgiani JN, et al: Development of interpretive break-points for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997; 24:235-247
24. Wisplinghoff H, Bischoff T, Tallent SM, et al: Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004; 39:309 -317; erratum in Clin Infect Dis 2004; 39:1093
25. Vincent JL, Anaissie E, Bruining H, et al: Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med 1998; 24:206-216
26. Eggimann P, Garbino J, Pittet D: Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003; 3:685-702
27. Maenza JR, Merz WG: Candidemia: Epidemiology and laboratory detection. Inf Dis Clin Pract 1997; 6:83-88
28. Solomkin JS, Flohr AB, Quie PG, et al: The role of Candida in intraperitoneal infections. Surgery 1980; 88:524-530
29. Krause RJ, Matheis H, Wulf K: Fungaemia and funguria after oral administration of Candida albicans. Lancet 1969; 1:598-599
30. Voss A, Hollis RJ, Pfaller MA, et al: Investigation of the sequence of colonization and candidemia in nonneutropenic patients. J Clin Microbiol 1994; 32:975-980
31. Petri MG, Konig J, Moecke HP, et al: Epidemiology of invasive mycosis in ICU patients: A prospective multicenter study in 435 non-neutropenic patients. Paul-Ehrlich Society for Chemotherapy, Divisions of Mycology and Pneumonia Research. Intensive Care Med 1997; 23:317-325
32. Pelz R, Lipsett PA, Swoboda SM, et al: The diagnostic value of fungal surveillance cultures in critically ill patients. Surg Infect (Larchmt) 2000; 1:273-281
33. Charles PE, Dalle F, Aube H, et al: Candida spp. colonization significance in critically ill medical patients: A prospective study. Intensive Care Med 2005; 31:393-400
34. Pelz R, Hendrix C, Swoboda S, et al: A double blind placebo controlled trail of prophylactic fluconazole to prevent Candida infections in critically ill surgical patients. Ann Surg 2001; 233:542-548
35. Nieto-Rodriguez J, Kusne S, Manez R, et al: Factors associated with the development of candidemia and candidemia-related death among liver transplant recipients. Ann Surg 1996; 223:70-76
36. Lumbreras C, Cuervas-Mons V, Jara P, et al: Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis 1996; 174:583-588
37. Hadley S, Karchmer AW: Fungal infections in solid organ transplant recipients. Infect Dis Clin North Am 1995; 9:1045-1074
38. Winston DJ, Pakrasi A, Busuttil RW: Prophylactic fluconazole in liver transplant recipients: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131: 729-737
39. Benedetti E, Gruessner AC, Troppmann C, et al: Intra-abdominal fungal infections after pancreatic transplantation: Incidence, treatment, and outcome. J Am Coll Surg 1996; 183:307-316
40. Kusne S, Furukawa H, Abu-Elmagd K, et al: Infectious complications after small bowel transplantation in adults: An update. Transplant Proc 1996; 28:2761-2762
41. Borzotta AP, Beardsley K: Candida infections in critically ill trauma patients: A retrospective case-control study. Arch Surg 1999; 134: 657-664
42. Calandra T, Bille J, Schneider R, et al: Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 1989; 2:1437-1440
43. Sandven P, Qvist H, Skovlund E, et al: Significance of Candida recovered from intraoperative specimens in patients with intraabdominal perforations. Crit Care Med 2002; 30:541-547
44. Collins LA, Samore MH, Roberts MS, et al: Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994; 170:644-652
45. Singh N, Paterson DL: Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18:44-69
46. Isenberg HD, Tucci V, Cintron F, et al: Single-source outbreak of Candida tropicalis complicating coronary bypass surgery. J Clin Microbiol 1989; 11:2426-2428
47. Weems JJ Jr, Chamberland ME, Ward J, et al: Candida parapsilosis fungemia associated with parenteral nutrition and contaminated blood pressure transducers. J Clin Microbiol 1987; 25:1029-1032
48. Ahmed S, Kahn Z, Mustafa AS, et al: Epidemiology of Candida colonization in an intensive care unit of a teaching hospital in Kuwait. Med Mycol 2003; 41:487-493
49. Pappas PG, Rex JH, Sobel JD, et al: Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38:161-189
50. Edwards JE Jr, Bodey GP, Bowden RA, et al: International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997; 25:43-59
51. Masur H, Rosen PP, Armstrong D: Pulmonary disease caused by Candida species. Am J Med 1977; 63:914-925
52. El-Ebiary M, Torres A, Fabrega N, et al: Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. Am J Respir Crit Care Med 1997; 156:583-590
53. Kauffman CA, Vazquez JA, Sobel JD, et al: Prospective multicenter surveillance study of funguria in hospitalized patients. Clin Infect Dis 2000; 30:14-18
54. Nassoura Z, Ivatury RR, Simon RJ, et al: Candiduria as an early marker of disseminated infection in critically ill surgical patients: The role of fluconazole therapy. J Trauma 1993; 35:290-295
55. Alvarez-Lerma F, Nolla-Salas J, Leon C, et al: Candiduria in critically ill patients admitted to intensive care medical units. Intensive Care Med 2003; 29:1069-1076
56. Rex JH, Sobel JD: Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 2001; 32:1191-1200
57. Piarroux R, Grenouillet F, Balvay P, et al: Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004; 32:2552-2553
58. Ascioglu S, Rex JH, DePauw B, et al: Defining opportunistic invasive fungal infections in immunocompromised patients with cancer in hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34:7-14
59. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al: Multicenter clinical evaluation of the (1->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41:654-659
60. Ostrosky-Zeichner L: Prophylaxis and treatment of invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2004; 23:739-744
61. Blot S, Vandewoude K: Management of invasive candidiasis in critically ill patients. Drugs 2004; 64:2159-2175
62. Garrelts JC, Schroeder TR, Harrison PB: Impact of fluconazole administration on outcomes in critically ill patients. Ann Pharmacother 2004; 38:1588-1592
63. Gleason TG, May AK, Caparelli D, et al: Emerging evidence of selection of fluconazole-tolerant fungi in surgical intensive care units. Arch Surg 1997; 132:1197-1201
64. Ostrosky-Zeichner L, Oude Lashof AM, Kullberg BJ, et al: Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003; 22:651-655
65. Bennett JE, Powers J, Walsh T, et al: Forum report: Issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2003; 36(Suppl 3):S117-S122
66. Kauffman CA: New antifungal agents. Semin Respir Crit Care Med 2004; 25:233-239
67. Kontoyiannis DP, Bodey GP, Mantzoros CS: Fluconazole vs. amphotericin B for the management of candidaemia in adults: A metaanalysis. Mycoses 2001; 44:125-135
68. Rex JH, Bennett JE, Sugar AM, et al: A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia: Candidemia Study Group and the National Institute. N Engl J Med 1994; 331:1325-1330
69. Mora-Duarte J, Betts R, Rotstein C, et al: Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347:2020-2029
70. Anaissie EJ, Rex JH, Uzun O, et al: Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998; 104:238-245
71. Varghese JC, Hahn PF, Harisinghani MG, et al: Fungus-infected fluid collections in thorax or abdomen: Effectiveness of percutaneous catheter drainage. Radiology 2005; 236: 730-738
72. Rex JH, Bennett JE, Sugar AM, et al: Intravascular catheter exchanges and the duration of candidemia. Clin Infect Dis 1995; 21: 994-996
73. Baddley JW, Pappas PG: Antifungal combination therapy: Clinical potential. Drugs 2005; 65:1461-1480
74. Abele-Horn M, Kopp A, Sternberg U, et al: A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care experimental candidiasis. Infection 1996; 24:426-432
75. Rex JH, Pappas PG, Karchmer AW, et al: A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic subjects. Clin Infect Dis 2003; 36:1221-1228
76. Sobel JD, Kauffman CA, McKinsey D, et al: Candiduria: A randomized, double blind study of treatment with fluconazole and placebo. Clin Infect Dis 2000; 30:19-24
77. Savino JA, Agarwal N, Wry P, et al: Routine prophylactic antifungal agents in nontransplant/nonburned critically ill surgical and trauma patients. J Trauma 1994; 36:20-26
78. Eggimann P, Francioli P, Bille J, et al: Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27:1066-1072
79. Ables AZ, Blumer NA, Valanis GT, et al: Fluconazole prophylaxis of severe Candida infection in trauma and post-surgical patients: A prospective, double-blind randomized, placebo-controlled trail. Infect Dis Clin Pract 2000; 9:169-175
80. Garbino J, Lew DP, Romand JA, et al: Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: A randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002; 28:1708-1717
81. Pelz RK, Lipsett PA, Swoboda SM, et al: Enteral fluconazole is well absorbed in critically ill surgical patients. Surgery 2002; 131: 534-540
82. Swoboda SM, Merz WG, Lipsett PA: Candidemia: The impact of antifungal prophylaxis in a surgical intensive care unit. Surg Infect 2003; 4:345-354
83. Pelz R, Lipsett PA, Swoboda SM, et al: Candida infections: Outcome and attributable ICU costs in critically ill patients. J Intensive Care Med 2000; 15:255-261
84. Rentz AM, Halpern MT, Bowden R: The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998; 27:781-788
85. Gloor B, Muller CA, Worni M, et al: Pancreatic infection in severe pancreatitis: The role of fungus and multi resistant organisms. Arch Surg 136:592-596
86. De Waele JJ, Vogelaers D, Blot S, et al: Fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy. Clin Infect Dis 2003; 37: 208 -213
87. Goff DA, Sierawski SJ, Fass RJ: Cost analysis of Candida infection among surgical intensive care unit patients. Clin Drug Invest 1996; 12:176-180
88. Olaechea PM, Palomar M, Leon-Gil C, et al: Economic impact of Candida colonization and Candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis 2004; 23:323-330